<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04553835</url>
  </required_header>
  <id_info>
    <org_study_id>HSEARS20200630002</org_study_id>
    <nct_id>NCT04553835</nct_id>
  </id_info>
  <brief_title>Effects of Rhythmic Auditory Stimulation on Movements in Individuals at Risk for Psychotic Onset and Schizophrenia Patients</brief_title>
  <official_title>Effects of Rhythmic Auditory Stimulation on Movements in Individuals at Risk for Psychotic Onset and Schizophrenia Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr WANG Shumei</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Hong Kong Polytechnic University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to examine effects of movement training with the aid of&#xD;
      rhythmic auditory stimulation (RAS) on reducing severity of dyskinesia and bradykinesia in&#xD;
      at-risk individuals and schizophrenia patients. The investigators hypothesize that training&#xD;
      with the aid of RAS reduced severity of bradykinesia and dyskinesia in at-risk individuals as&#xD;
      well as in schizophrenia patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 31, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Motion analysis by using an eight-camera motion capture system (VICON; Oxford Metrics Group, Oxford, UK)</measure>
    <time_frame>Within one week right before the 1st session of the intervention</time_frame>
    <description>normalized movement time (representing severity of parkinsonism). Unit: second/mm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Motion analysis by using an eight-camera motion capture system (VICON; Oxford Metrics Group, Oxford, UK)</measure>
    <time_frame>Within one week right after the last session of the intervention</time_frame>
    <description>normalized movement time (representing severity of parkinsonism). Unit: second/mm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Motion analysis by using an eight-camera motion capture system (VICON; Oxford Metrics Group, Oxford, UK)</measure>
    <time_frame>Within one week right before the 1st session of the intervention</time_frame>
    <description>normalized number of movement units (representing severity of dyskinesia). Unit: units/mm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Motion analysis by using an eight-camera motion capture system (VICON; Oxford Metrics Group, Oxford, UK)</measure>
    <time_frame>Within one week right after the last session of the intervention</time_frame>
    <description>normalized number of movement units (representing severity of dyskinesia). Unit: units/mm</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Psychosis</condition>
  <condition>Parkinsonism</condition>
  <condition>Dyskinesias</condition>
  <arm_group>
    <arm_group_label>schizophrenia- RAS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Schizophrenia patients in the experimental group will undergo upper-limb movement training with the aid of rhythmic auditory stimulation (RAS).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>schizophrenia- no RAS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Schizophrenia patients in the control group will receive upper-limb training without the aid of RAS.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>at risk- RAS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>At-risk individuals in the experimental group will undergo upper-limb movement training with the aid of RAS.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>at risk- no RAS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>At-risk individuals in the control group will receive upper-limb training without the aid of RAS.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Rhythmic auditory stimulation (RAS) for schizophrenia patients</intervention_name>
    <description>A mobile application, &quot;metronome beats&quot; developed by Stonekick Limited, will be used to give RAS when the participant executes the movement. Before intervention, the participant is required to execute the movement task without the aid of RAS as quickly as possible for 30 seconds, so that we obtain his/her baseline movement tempo (beats per minute). For each 40-minute training session in the first training week, three RAS tempi will be provided for the first, second, and last 10 minutes with a five-minute break in between: normal (100% of the baseline tempo), quick (105% of the baseline tempo), and fast (110% of the baseline tempo). With each training week, the three RAS tempi will be increased by 5%. Schizophrenia patients in the experimental group will undergo upper limb movement training with the aid of RAS. The intervention protocol will last for 3 weeks on the weekday basis (a total of 15 sessions) with one session (40 minutes) per weekday.</description>
    <arm_group_label>schizophrenia- RAS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>No RAS for schizophrenia patients</intervention_name>
    <description>The training protocol will be the same as that used in the experimental group except the lack of RAS during execution of the movement task.</description>
    <arm_group_label>schizophrenia- no RAS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>RAS for at-risk individuals</intervention_name>
    <description>A mobile application, &quot;metronome beats&quot; developed by Stonekick Limited, will be used to give RAS when the participant executes the movement. Before intervention, the participant is required to execute the movement task without the aid of RAS as quickly as possible for 30 seconds, so that we obtain his/her baseline movement tempo (beats per minute). For each 40-minute training session in the first training week, three RAS tempi will be provided for the first, second, and last 10 minutes with a five-minute break in between: normal (100% of the baseline tempo), quick (105% of the baseline tempo), and fast (110% of the baseline tempo). With each training week, the three RAS tempi will be increased by 5%. At-risk individuals in the experimental group will undergo upper limb movement training with the aid of RAS. The intervention protocol will last for 3 weeks on daily basis (a total of 21 sessions), with one training session (40 minutes) per day.</description>
    <arm_group_label>at risk- RAS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>No RAS for at-risk individuals</intervention_name>
    <description>The training protocol will be the same as that used in the experimental group except the lack of RAS during execution of the movement task.</description>
    <arm_group_label>at risk- no RAS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For at-risk individuals:&#xD;
&#xD;
        The inclusion criteria for at-risk individuals are:&#xD;
&#xD;
          1. A score of or above 9 in the Chinese version of the 16-item Prodromal Questionnaire&#xD;
             (CPQ-16), or a score of or above 8.18 in the Chinese version of Community Assessment&#xD;
             of Psychic Experiences with 15 items (CAPE-C15), or a score of or above 17 in&#xD;
             Schizotypal Personality Questionnaire-Brief (SPQ-B);&#xD;
&#xD;
          2. A score of or above 22 in the Hong Kong version of Montreal Cognitive Assessment&#xD;
             (HK-MoCA) to ensure that they can understand instructions;&#xD;
&#xD;
          3. A score of or above 60 in the Chinese Version of Edinburgh Handedness Inventory to&#xD;
             ensure that they are right-handed.&#xD;
&#xD;
          4. The age ≥ 13 years.&#xD;
&#xD;
        The inclusion criteria for healthy controls are:&#xD;
&#xD;
          1. A score below the cut-off score of CPQ-16, CAPE-C15, and SPQ-B;&#xD;
&#xD;
          2. A score of or above 22 in MoCA;&#xD;
&#xD;
          3. A score of or above 60 in the Chinese Version of Edinburgh Handedness Inventory;&#xD;
&#xD;
          4. No first-degree family members having a diagnosis of mental illnesses.&#xD;
&#xD;
          5. The age ≥ 13 years.&#xD;
&#xD;
        At-risk participants and healthy controls will be excluded if they have any neurological /&#xD;
        musculoskeletal dysfunction that may affect their upper-limb movements.&#xD;
&#xD;
        For schizophrenia patients:&#xD;
&#xD;
        The inclusion criteria for schizophrenia patients are:&#xD;
&#xD;
          1. A diagnosis of schizophrenia without other psychiatric diseases;&#xD;
&#xD;
          2. Having stable psychotic symptoms;&#xD;
&#xD;
          3. A score of or above 22 in HK-MoCA;&#xD;
&#xD;
          4. A score of or above 60 in the Chinese Version of Edinburgh Handedness Inventory.&#xD;
&#xD;
          5. The age ≥ 18 years.&#xD;
&#xD;
        The inclusion criteria for healthy controls are:&#xD;
&#xD;
          1. A score below the cut-off score of CPQ-16, CAPE-C15, and SPQ-B;&#xD;
&#xD;
          2. A score of or above 22 in MoCA;&#xD;
&#xD;
          3. A score of or above 60 in the Chinese Version of Edinburgh Handedness Inventory;&#xD;
&#xD;
          4. No first-degree family members having a diagnosis of mental illnesses.&#xD;
&#xD;
          5. The age ≥ 18 years.&#xD;
&#xD;
        Patients and healthy controls will be excluded if they have any neurological /&#xD;
        musculoskeletal dysfunction that may affect their upper-limb movements.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shu-Mei Wang, PhD</last_name>
    <phone>852-27664197</phone>
    <email>shumei.wang@polyu.edu.hk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hong Kong Polytechnic University</name>
      <address>
        <city>Kowloon</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shu-Mei Wang, PhD</last_name>
      <phone>852-27664197</phone>
      <email>shumei.wang@polyu.edu.hk</email>
    </contact>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 12, 2020</study_first_submitted>
  <study_first_submitted_qc>September 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2020</study_first_posted>
  <last_update_submitted>September 16, 2020</last_update_submitted>
  <last_update_submitted_qc>September 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>The Hong Kong Polytechnic University</investigator_affiliation>
    <investigator_full_name>Dr WANG Shumei</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyskinesias</mesh_term>
    <mesh_term>Parkinsonian Disorders</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

